Overexpression of these ligands on the tumor is usually associated with poorer prognosis for patients: increased tumor expression of CD112 correlates with increased tumor size and stage, in cancers of the gallbladder (265), colon (266), ovary (267), and pancreas (268). The gene discussed is NECTIN2; the disease is neoplasm.